Edwards Lifesciences Corp Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Edwards Lifesciences Corp quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Edwards Lifesciences Corp Operating Income (Loss) for the quarter ending September 30, 2024 was $351M, a 4.18% decline year-over-year.
  • Edwards Lifesciences Corp Operating Income (Loss) for the twelve months ending September 30, 2024 was $1.62B, a 10.8% increase year-over-year.
  • Edwards Lifesciences Corp annual Operating Income (Loss) for 2023 was $1.53B, a 12.3% decline from 2022.
  • Edwards Lifesciences Corp annual Operating Income (Loss) for 2022 was $1.75B, a 3.44% increase from 2021.
  • Edwards Lifesciences Corp annual Operating Income (Loss) for 2021 was $1.69B, a 88.3% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.62B $351M -$15.3M -4.18% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $1.64B $369M +$106M +40.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $1.53B $388M -$900K -0.23% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-29
Q4 2023 $1.53B $516M +$68.5M +15.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 $1.47B $366M -$36.5M -9.07% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $1.5B $264M -$196M -42.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $1.7B $388M -$50.4M -11.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-29
Q4 2022 $1.75B $448M +$73.4M +19.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 $1.68B $402M +$12.1M +3.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-27
Q2 2022 $1.66B $460M -$82.6M -15.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-28
Q1 2022 $1.75B $439M +$55.3M +14.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-28
Q4 2021 $1.69B $374M +$23M +6.55% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $1.67B $390M +$32.5M +9.08% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $1.63B $542M +$712M Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-29
Q1 2021 $923M $384M +$25.4M +7.09% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 $898M $351M +$40.6M +13.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-13
Q3 2020 $857M $358M +$63.5M +21.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $794M -$170M -$437M -163% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $1.23B $358M +$83.9M +30.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 $1.15B $311M +$316M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-14
Q3 2019 $831M $294M +$45.4M +18.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-26
Q2 2019 $785M $268M +$15.4M +6.11% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-27
Q1 2019 $770M $274M +$21.7M +8.59% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q4 2018 $748M -$5.3M -$341M -102% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-12
Q3 2018 $1.09B $249M +$34.9M +16.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-25
Q2 2018 $1.05B $252M +$11.1M +4.61% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-26
Q1 2018 $1.04B $253M -$45.8M -15.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-26
Q4 2017 $1.09B $336M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-14
Q3 2017 $214M Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-26
Q2 2017 $241M Apr 1, 2017 Jun 30, 2017 10-Q 2018-07-27
Q1 2017 $298M Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.